vs
百特国际（BAX）与Tennessee Valley Authority（TVE）财务数据对比。点击上方公司名可切换其他公司
Tennessee Valley Authority的季度营收约是百特国际的1.0倍（$3.0B vs $3.0B），Tennessee Valley Authority净利率更高（8.7% vs -37.9%，领先46.7%），百特国际同比增速更快（458.0% vs 4.4%），过去两年Tennessee Valley Authority的营收复合增速更高（-1.7% vs -9.0%）
百特国际是总部位于美国伊利诺伊州迪尔菲尔德的跨国医疗健康企业，业务布局覆盖全球众多市场，专注于研发、生产及销售各类医疗相关产品与解决方案，为全球医疗机构和患者提供专业可靠的医疗支持。
田纳西河流域管理局（TVA）是美国联邦政府所有的电力公用事业企业，服务范围覆盖田纳西州全境，以及阿拉巴马州、密西西比州、肯塔基州的部分区域，还涵盖佐治亚州、北卡罗来纳州、弗吉尼亚州的小块区域。该企业虽归属联邦政府，但不依赖纳税人资金运营，运营模式与私营盈利企业类似，总部位于田纳西州诺克斯维尔。
BAX vs TVE — 直观对比
营收规模更大
TVE
是对方的1.0倍
$3.0B
营收增速更快
BAX
高出453.6%
4.4%
净利率更高
TVE
高出46.7%
-37.9%
两年增速更快
TVE
近两年复合增速
-9.0%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $3.0B | $3.0B |
| 净利润 | $-1.1B | $266.0M |
| 毛利率 | 19.4% | — |
| 营业利润率 | -24.5% | 18.1% |
| 净利率 | -37.9% | 8.7% |
| 营收同比 | 458.0% | 4.4% |
| 净利润同比 | -120.3% | 112.8% |
| 每股收益（稀释后） | $-2.21 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BAXTVE
| Q4 25 | $3.0B | $3.0B | ||
| Q3 25 | $2.8B | $3.9B | ||
| Q2 25 | $2.8B | $3.3B | ||
| Q1 25 | $2.6B | $3.5B | ||
| Q4 24 | $533.0M | $2.9B | ||
| Q3 24 | $2.7B | $3.5B | ||
| Q2 24 | $3.8B | $2.9B | ||
| Q1 24 | $3.6B | $3.2B |
净利润BAXTVE
| Q4 25 | $-1.1B | $266.0M | ||
| Q3 25 | $-46.0M | $615.0M | ||
| Q2 25 | $91.0M | $212.0M | ||
| Q1 25 | $126.0M | $408.0M | ||
| Q4 24 | $-512.0M | $125.0M | ||
| Q3 24 | $140.0M | $520.0M | ||
| Q2 24 | $-314.0M | $181.0M | ||
| Q1 24 | $37.0M | $307.0M |
毛利率BAXTVE
| Q4 25 | 19.4% | — | ||
| Q3 25 | 33.5% | — | ||
| Q2 25 | 35.3% | — | ||
| Q1 25 | 32.8% | — | ||
| Q4 24 | 25.0% | — | ||
| Q3 24 | 38.3% | — | ||
| Q2 24 | 37.5% | — | ||
| Q1 24 | 38.6% | — |
营业利润率BAXTVE
| Q4 25 | -24.5% | 18.1% | ||
| Q3 25 | 6.1% | 23.6% | ||
| Q2 25 | 6.8% | 15.6% | ||
| Q1 25 | 2.2% | 20.3% | ||
| Q4 24 | -25.5% | 14.1% | ||
| Q3 24 | 5.7% | 22.7% | ||
| Q2 24 | -5.0% | 15.9% | ||
| Q1 24 | 5.2% | 18.4% |
净利率BAXTVE
| Q4 25 | -37.9% | 8.7% | ||
| Q3 25 | -1.6% | 15.7% | ||
| Q2 25 | 3.2% | 6.4% | ||
| Q1 25 | 4.8% | 11.6% | ||
| Q4 24 | -96.1% | 4.3% | ||
| Q3 24 | 5.2% | 14.8% | ||
| Q2 24 | -8.2% | 6.3% | ||
| Q1 24 | 1.0% | 9.7% |
每股收益（稀释后）BAXTVE
| Q4 25 | $-2.21 | — | ||
| Q3 25 | $-0.09 | — | ||
| Q2 25 | $0.18 | — | ||
| Q1 25 | $0.25 | — | ||
| Q4 24 | $-0.99 | — | ||
| Q3 24 | $0.27 | — | ||
| Q2 24 | $-0.62 | — | ||
| Q1 24 | $0.07 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $2.0B | $501.0M |
| 总债务越低越好 | $9.5B | — |
| 股东权益账面价值 | $6.1B | — |
| 总资产 | $20.1B | $59.5B |
| 负债/权益比越低杠杆越低 | 1.55× | — |
8季度趋势，按日历期对齐
现金及短期投资BAXTVE
| Q4 25 | $2.0B | $501.0M | ||
| Q3 25 | $1.7B | $1.6B | ||
| Q2 25 | $1.7B | $501.0M | ||
| Q1 25 | $2.3B | $502.0M | ||
| Q4 24 | $1.8B | $507.0M | ||
| Q3 24 | $1.4B | $502.0M | ||
| Q2 24 | $2.1B | $501.0M | ||
| Q1 24 | $3.0B | $508.0M |
总债务BAXTVE
| Q4 25 | $9.5B | — | ||
| Q3 25 | — | $22.1B | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $10.4B | — | ||
| Q3 24 | $10.4B | $19.1B | ||
| Q2 24 | $10.4B | — | ||
| Q1 24 | $11.1B | — |
股东权益BAXTVE
| Q4 25 | $6.1B | — | ||
| Q3 25 | $7.2B | — | ||
| Q2 25 | $7.3B | — | ||
| Q1 25 | $7.1B | — | ||
| Q4 24 | $7.0B | — | ||
| Q3 24 | $7.9B | — | ||
| Q2 24 | $7.6B | — | ||
| Q1 24 | $8.2B | — |
总资产BAXTVE
| Q4 25 | $20.1B | $59.5B | ||
| Q3 25 | $21.1B | $60.9B | ||
| Q2 25 | $21.0B | $59.9B | ||
| Q1 25 | $21.3B | $59.3B | ||
| Q4 24 | $25.8B | $58.4B | ||
| Q3 24 | $26.7B | $57.7B | ||
| Q2 24 | $26.3B | $56.2B | ||
| Q1 24 | $27.8B | $52.3B |
负债/权益比BAXTVE
| Q4 25 | 1.55× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 1.49× | — | ||
| Q3 24 | 1.33× | — | ||
| Q2 24 | 1.37× | — | ||
| Q1 24 | 1.36× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $584.0M | $330.0M |
| 自由现金流经营现金流 - 资本支出 | — | $-814.0M |
| 自由现金流率自由现金流/营收 | — | -26.7% |
| 资本支出强度资本支出/营收 | — | 37.5% |
| 现金转化率经营现金流/净利润 | — | 1.24× |
| 过去12个月自由现金流最近4个季度 | — | $-1.2B |
8季度趋势，按日历期对齐
经营现金流BAXTVE
| Q4 25 | $584.0M | $330.0M | ||
| Q3 25 | $237.0M | $1.2B | ||
| Q2 25 | $217.0M | $615.0M | ||
| Q1 25 | $-193.0M | $1.0B | ||
| Q4 24 | $488.0M | $450.0M | ||
| Q3 24 | $253.0M | $1.1B | ||
| Q2 24 | $115.0M | $508.0M | ||
| Q1 24 | $163.0M | $1.0B |
自由现金流BAXTVE
| Q4 25 | — | $-814.0M | ||
| Q3 25 | — | $233.0M | ||
| Q2 25 | — | $-431.0M | ||
| Q1 25 | — | $-176.0M | ||
| Q4 24 | — | $-759.0M | ||
| Q3 24 | — | $164.0M | ||
| Q2 24 | — | $-248.0M | ||
| Q1 24 | — | $276.0M |
自由现金流率BAXTVE
| Q4 25 | — | -26.7% | ||
| Q3 25 | — | 6.0% | ||
| Q2 25 | — | -13.0% | ||
| Q1 25 | — | -5.0% | ||
| Q4 24 | — | -26.0% | ||
| Q3 24 | — | 4.7% | ||
| Q2 24 | — | -8.6% | ||
| Q1 24 | — | 8.8% |
资本支出强度BAXTVE
| Q4 25 | — | 37.5% | ||
| Q3 25 | — | 25.9% | ||
| Q2 25 | — | 31.6% | ||
| Q1 25 | — | 33.6% | ||
| Q4 24 | — | 41.4% | ||
| Q3 24 | — | 25.6% | ||
| Q2 24 | — | 26.3% | ||
| Q1 24 | — | 24.2% |
现金转化率BAXTVE
| Q4 25 | — | 1.24× | ||
| Q3 25 | — | 2.03× | ||
| Q2 25 | 2.38× | 2.90× | ||
| Q1 25 | -1.53× | 2.48× | ||
| Q4 24 | — | 3.60× | ||
| Q3 24 | 1.81× | 2.05× | ||
| Q2 24 | — | 2.81× | ||
| Q1 24 | 4.41× | 3.38× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BAX
| Other | $1.5B | 51% |
| Infusion Therapies And Technologies | $543.0M | 18% |
| Pharmaceutical Compounding | $316.0M | 11% |
| Front Line Care | $219.0M | 7% |
| Injectables And Anesthesia | $190.0M | 6% |
| Advanced Surgery | $177.0M | 6% |
TVE
| TN | $2.0B | 65% |
| AL | $449.0M | 15% |
| MS | $266.0M | 9% |
| KY | $193.0M | 6% |
| GA | $75.0M | 2% |
| Federal Agencies And Other | $29.0M | 1% |
| NC | $23.0M | 1% |
| VA | $12.0M | 0% |
| Off System Sales Member | $2.0M | 0% |
